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Safety of a formulation containing chitosan microparticles with 
chamomile: blind controlled clinical trial*
Objective: to evaluate the safety of a topical formulation containing chamomile microparticles 
coated with chitosan in the skin of healthy participants. Method: phase I blind, controlled, non-
randomized, single-dose clinical trial with control for skin, base formulation, and formulation 
with microparticles. The variables analyzed were irritation and hydration by the Wilcoxon and 
Kruskall-Wallis tests. Results: the study started with 35 participants with a mean age of 26.3 
years. Of these, 30 (85.71%) were female, 29 (82.90%) were white skinned and 32 (91.40%) 
had no previous pathologies. One participant was removed from the study reporting erythema 
at the site of application, and four other participants for not attending the last evaluation. In 
the 30 participants who completed the study, the tested formulation did not cause erythema, 
peeling, burning, pruritus or pain; there was an improvement in cutaneous hydration in the site 
of application of the formulation with microparticles. In the evaluation of the barrier function, 
there was an increase in transepidermal water loss in all sites. Conclusion: the formulation 
with chamomile microparticles is safe for topical use, not causing irritation and improving skin 
hydration over four weeks of use. Its effects on barrier function need further investigation. No. 
RBR-3h78kz in the Brazilian Registry of Clinical Trials (ReBEC).
Descriptors: Matricaria; Dermatologic Agents; Prevention and Control; Nursing; Clinical Trial; 
Medicinal Plants.
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Introduction
The skin, as the interface of the human body with 
the external environment, carries part of our identity: 
it provides information about our age, genetics, health 
status, lifestyle and even our emotional state(1). The 
skin has different roles, among them, the function of 
barrier, thermoregulation, vitamin D synthesis and also 
protection of the body against harmful agents(2-3).
Currently, there is a growing interest on skin care 
products and their protective and healing properties, 
especially those with botanical extracts(4). Among the 
latter, Chamomilla recutita (L.) rauschert (chamomile) 
is a popular plant(5) which has its use as a phytotherapic 
released by the National Agency of Sanitary Surveillance 
(ANVISA)(6). Chamomile has flavonoids, among which 
apigenin and apigenin-7-glycoside are the most 
abundant(7). In different studies, these substances 
have proved to have antimicrobial(8), analgesic(9), anti-
inflammatory(6,8,10-11), cicatrizant(12-13), antitumor(14-15) and 
immunomodulator(16) potential. Moreover, the antioxidant 
blend present in chamomile extract is effective in 
reducing free radicals and brings potential benefits 
when used in skin formulations by reducing water loss, 
improving hydration, and aiding the maintenance of the 
barrier function(4).
The risks associated with the use of this plant 
are small and are related to the reduction of platelet 
aggregation(17) and anaphylactic reactions to people 
sensitive to its components(18). However, a recent study 
that evaluated allergic reactions to herbal compounds 
over the last 27 years found no reports related to 
Chamomilla recutita (L.) rauschert(19).
Despite the potential of apigenin and apigenin-7-
glycoside, they have low stability(15,20-22). An alternative 
to improve this issue is the use of controlled release 
systems. The pharmaceutical sector, in line with 
technological developments, has gradually improved the 
processes of obtaining different products and invested in 
the forms of producing and applying them. To this end, 
microencapsulation is a widely used technology aimed 
at optimizing industrial processes as well as increasing 
the bioavailability and stability of the formulations. This 
process can be accomplished by different methods, 
using various coatings. In this study, the selected 
coating was chitosan and the method of production was 
spray drying(21).
Chitosan is a biocompatible, biodegradable, low-
toxicity hydrophilic polysaccharide with mucoadhesive 
and film-forming properties(23). Studies point to its 
potential in the treatment of skin lesions, with positive 
results in cicatrization and inflammatory response(24-28). 
This polymer was also used to coat microparticles 
containing endothelial and epidermal growth factors, 
with positive results in improving the cicatrization 
process(29), and also as a coating of microparticles 
capable of capturing and expanding specific cells in order 
to accelerate the anti-inflammatory and cicatrization 
processes(30).
Despite all the potentialities of chitosan-coated 
microparticles and the therapeutic properties of 
chamomile, no studies with these compounds were 
identified in the literature. These microparticles are 
incorporated in lanolin-based formulation, a safe 
substance for topical applications that incorporates 
various bioactive agents(31).
In view of the above, a study was carried out to 
evaluate the safety of the topical formulation containing 
chitosan-coated Chamomilla recutita (L.) Rauschert 
microparticles for application on the skin of healthy 
volunteers evaluating the following variables: erythema, 
variation in the amount of melanin, desquamation, 
burning, pruritus, pain and alterations in cutaneous 
hydration. The hypothesis was that the use of this 
formulation would be safe for cutaneous application over 
four weeks of use.
Method
Blind, controlled, non-randomized, single-dose 
Phase I clinical trial in which a low dose with biological 
activity of the active ingredient was administered(32).
Extraction and microencapsulation methodologies 
developed and validated in a previous study were applied 
for the development of the microparticles used in this 
study(21). Quality tests of the plant acquired according 
to the guidelines of the Brazilian Pharmacopoeia(34) were 
carried out in another study developed by the main 
author, as well as preliminary permeation and stability 
tests of the formulation in an ex vivo model.
The formulations were prepared at the Laboratory 
of Industrial Pharmaceutical Development of the School 
of Pharmaceutical Sciences of Ribeirão Preto, University 
of São Paulo (LADIFARP/FCFRP/USP). The formulation 
with Chamomile (F1) had 99.8% of Lanolin and 0.2% 
of microparticles, and Formulation without Chamomile 
(F2) had 100% of Lanolin. The dose of chamomile in 
the microparticles and consequently in the formulation 
was selected based on the guidelines established by 
ANVISA(6) for the amount of apigenin-7-glycoside.
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The criteria for inclusion of participants were: 
age (18 years and over); healthy skin in the site of 
application of the product (forearms); absence of history 
of hypersensitivity to fish, seafood or any component 
of the formulation (chamomile, chitosan or lanolin); 
non-use of heparin, oral anticoagulants, and antiplatelet 
agents. The exclusion criteria were: injury at the sites 
of application, express intention to stop participation, 
and non-application of the product for more than four 
consecutive days.
National(35) and international(32) recommendations 
about studies aiming at the initial evaluations of tolerance 
and safety in healthy humans were considered; the 
participation of 20 to 100 individuals is recommended.
The study was carried out in partnership with the 
Nucleus of Advanced Studies in Cosmetic Technology at 
the School of Pharmaceutical Sciences of Ribeirão Preto, 
University of São Paulo (NEATEC/FCFRP/USP), whose 
laboratory is equipped for skin analysis. Participants 
were recruited through an invitation made personally 
by the principal investigator in the university during the 
period from August to September 2015.
The four evaluation sites of each participant 
were: two control sites of skin without application of 
any product, one in each forearm (C1 and C2); one 
control site of application of the formulation (F2); and 
one experimental site (F1). Thus, each participant 
presented four evaluation sites, two with application of 
formulations and two without application of formulations 
(Figure 1).
Right forearm
Without
formulation
(C1)
Without
formulation (C2)
Formulation with
microparticles
(F1)
Formulation
without
microparticles
(F2)
Left forearm
Figure 1. Scheme of sites of application of the product, 
control sites and site of evaluation of the skin
For the application of the formulations, the 
procedures were standardized as follows: the application 
site should be free of any spot, lesions, irritations or 
abrasions, as set out in the inclusion criteria; the 
amount of formulation was pre-determined at the tip 
of a spatula and applied separately; formulation 1 (F1) 
was applied on the anterior side of the right forearm and 
formulation (F2) on the anterior side of the left forearm; 
in the proximal portion of both, no product was applied 
to allow assessment of skin conditions (right negative 
control - C1; left negative control - C2). The dose was 
applied once a day, daily, always at the same time, and 
the participants were instructed not to use any other 
product at the application and evaluation sites during 
the 28 days of study.
Before each evaluation, all participants remained in 
a room with conditioned airat 24ºC (± 2ºC), with relative 
air humidity (RH) around 50% (± 4%), for 15 minutes. 
The skin area evaluated was demarcated with a ruler, 
to help performing all evaluations in the same sites. On 
the first day of treatment (D0), an initial evaluation of 
the skin was made and the participants were instructed 
about the procedures of application of the formulations 
and the standardization of the sites. Each participant 
received two pots containing information on expiration 
date and application, one for the left forearm and 
one for the right forearm. All participants used both 
formulations.
After 24 hours (D1) of the first application, the 
participants were evaluated for tolerance and onset of 
adverse reactions. If no complaints or signs of irritation 
were reported, the treatment was continued until the 
day D28, when the participants were re-evaluated.
The outcomes analyzed were skin irritation 
and hydration, evaluated by means of quantitative 
measurement instruments, clinical evaluation and 
subjective evaluation. Quantitative determinations of 
erythema and melanin were performed with Mexameter® 
MX18 (Courage and Khazaka Electronics Ltd, Koeln, 
Germany) and local skin pH was measured with a Skin-
pH-Meter pH 900® (Courage and Khazaka Electronics 
Ltd, Koeln, Germany). The visual clinical evaluation of 
macroscopic desquamation and the subjective evaluation 
were performed by inquiring the participants about the 
sensation of heat, burning, pruritus and pain. Skin 
hydration was evaluated by: the water content retained 
in the stratum corneum assessed with a Corneometer® 
CM 825 (Courage & Khazaka, Koeln, Germany); the 
transepidermal water loss assessed with a Tewameter® 
TM 210 (Courage and Khazaka Electronics Ltd, Koeln, 
Germany); clinical parameters of opacity and roughness; 
and a subjective evaluation of the participants regarding 
the sensation of hydration.
Quantitative measurements were performed 
by a pharmacist with experience in these analyses. 
The clinical evaluation was done by a nurse and the 
subjective evaluation by the participants themselves. 
All the results were annotated in a data collection 
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instrument previously submitted to three judges for the 
evaluation of content and face validity.
The nurse and pharmacist who conducted the 
evaluations, as well as the participants, did not know 
which formulation contained the chitosan microparticles 
with chamomile. Furthermore, given the typical odor and 
the consistency of Lanolin®, the control formulation (F2) 
presented the same appearance as the one in the test 
(F1).
A descriptive analysis of each variable was 
performed and their distribution was verified by the 
Kolmogorov-Smirnov test; the appropriate statistical 
test was chosen only after this test. The analyses were 
run in the SAS® software; a significance level (α) of 5% 
and power of 80% were adopted. The Wilcoxon test was 
chosen to evaluate the situation before and after the 
experiment in each application site. The Kruskal-Wallis 
test was used to compare the application sites of the 
formulations (F1 and F2) and controls (C1 and C2) at 
each moment.
The study was approved by the Research Ethics 
Committee of the College of Nursing of Ribeirão Preto 
(EERP/USP) under number 1,177,590/2015.
Results
A total of 52 participants were evaluated for eligibility 
and recruited by the principal investigator. Of these, 17 
did not attend the appointment; thus, 35 participants 
were allocated to the study. The study was completed 
after four weeks, according to the initial schedule plan. 
After initiation, one participant was removed from the 
study because of local irritation. He reported small red 
dots on the right forearm three hours after applying the 
formulation (F1), with spontaneous regression about 30 
minutes later. At the time of the evaluation of the D1, the 
site was unchanged and the participant reported no other 
complaints. For safety, this participant was instructed 
not to use the formulations and was removed from the 
study. Another four participants did not attend the final 
evaluation (D28), not concluding the proposed schedule. 
However, contact with these participants was maintained 
up to 21 days after application, when the date of the 
final evaluation was confirmed. We emphasize that until 
that date, none of these four participants had manifested 
any adverse reaction to the treatment. The flow of 
participants is shown in Figure 2.
Assessed for eligibility
(n=52)
Initial Allocation
(n=35 individuals, 4 forearm regions each)
F1*
(n=35 sites)
C1†
(n=35 sites)
F2‡
(n=35 sites)
C2§
(n=35 sites)
F1*
(n=34 sites)
C1†
(n=34 sites)
F2‡
(n=34 sites)
C2§
(n=34 sites)
F1*
(n=30 sites)
C1†
(n=30 sites)
F2‡
(n=30 sites)
C2§
(n=30 sites)
Follow-up
D1|| (n=34)
1 exclusion –
Local irritation
reaction
Seguimento
D28¶ (n=30)
4 exclusions –
Missed
follow-up
Recruitment
Did not attend the
scheduled appointment
(n=17)
* F1: Formulation with microparticles; †C1: Without formulation; ‡F2: Formulation without microparticles; §C2: Without formulation; ||D1: First day; ¶D28: Last day.
Figure 2. Flowchart of study participants according to CONSORT recommendations
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The mean age of the participants was 26.30 years 
(standard deviation 7.80, minimum 19, maximum 59), 
average body mass index (BMI) of 23.20 (standard 
deviation 4.42, minimum 16.1 , maximum 32.1). Other 
variables analyzed in the initial characterization of the 
participants are presented in Table 1.
Table 1. Sociodemographic and clinical characterization 
of participants at baseline (n = 35). Ribeirão Preto, SP, 
Brazil, 2015
Variables n (%)
Sex
Female 30 (85.7)
Male 5 (14.3)
Race 
White 29 (82.9)
Black 1 (2.9)
Brown 3 (8.6)
Asian 2 (5.7)
Personal history
None 32 (91.4)
DM * 1 (2.9)
Other 2 (5.7)
Alcohol consumption
No 5 (14.3)
Yes 0 (0.0)
Ex-alcoholic 1 (2.9)
Sporadic 29 (82.9)
Smoking
No 32 (91.4)
Yes 0 (0.0)
Ex-smoker 3 (8.6)
Sporadic 0 (0.0)
*DM: Diabetes Melitus
Firstly, an evaluation was carried out to identify 
possible differences in erythema, melanin, pH, 
hydration and transepidermal water loss between the 
four sites assessed at the beginning (D0) and at the 
end of the treatment (D28). These data are presented 
in Table 2.
Another evaluation was performed comparing 
each site before (D0) and after treatment (D28) in 
order to identify whether the use of the formulation 
significantly altered the mentioned parameters. Thus, 
no changes were observed in the clinical evaluation of 
the parameters of desquamation and edema after the 
first day of application or at the end of the four weeks. 
There was no difference between the initial and final 
mean values for erythema and melanin variables at any 
of the application sites, which confirms the expected 
results. This same analysis for the pH averages showed 
a difference between the initial and final values at the 
application site of the formulation with microparticles 
(p = 0.0492) and at the right control site (p = 0.0303) 
(Figure 3).
Table 2. Comparison of the means of erythema, melanin, 
pH, hydration and transepidermal water loss between 
the sites evaluated at the beginning (D0) and at the 
end of the treatment (D28) (n = 30). Ribeirão Preto, SP, 
Brazil, 2015
Variables
Beginning End
Mean p-value* Mean p-value*
Erythema
F1† 598.9
0.6464
599.1 0.8796
F2 ‡ 602.0 602.5
C1§ 601.1 603.8
C2|| 597.8 601.7
Melanin
F1† 483.1
0.0037¶
482.4 0.0053¶
F2 ‡ 486.4 487.3
C1§ 496.0 498.4
C2|| 492.9 496.3
pH
F1† 4.1
0.0819
4.6 0.0019¶
F2 ‡ 3.8 3.9
C1§ 3.7 4.4
C2|| 3.3 3.7
Water content
F1† 36.8
0.4837
40.3 0.1348
F2 ‡ 37.3 40.3
C1§ 38.8 43.1
C2|| 36.0 38.6
TEWL**
F1† 6.2
0.0006¶
9.1 0.0029¶
F2 ‡ 6.6 9.4
C1§ 4.5 7.4
C2|| 5.9 8.7
*Kruskal-Wallis test; †F1: Formulation with icroparticles; ‡F2: Formulation 
without microparticles; §C1: Without formulation; ||C2: Without 
formulation; ¶p-value < 0.05; **TEWL: Transepidermal water loss
There was an increase in the average hydration 
coefficient at the site of application of the formulation 
with microparticles (F1) (p = 0.0483) and in the right 
control (C1) (p = 0.0413). In relation to the skin barrier 
function, there was an increase in the average of 
transepidermal water loss (TEWL) in the four evaluated 
sites (F1 - p = 0.0003; F2 - p = 0.0004; C1 - p < 
0.0001; C2 - p <0.0001), indicating a decrease in the 
barrier function (Figure 3).
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*F1: Formulation with microparticles; †F2: Formulation without microparticles; ‡C1: Without formulation; §C2: Without formulation. || p-values less than 
0.05 (Wilcoxon Test).
Figure 3. Distribution of the mean values of erythema (a), melanin (b), pH (c), hydration (d) and TEWL (e) at the initial 
(D0) and final (D28) days in each evaluated site
The clinical evaluation of irritation did not find 
desquamation in any participant in the evaluated period. 
As for the subjective parameters of irritation (pain, 
burning, pruritus and heat), only one participant (3.3%) 
at the end of the four weeks of the study reported 
mild pain at the application site of the formulation with 
microparticles (F1), with rapid relief after a few minutes 
of application.
Regarding the clinical evaluation of skin hydration 
(opacity and roughness), no change was observed in D0 
or D28. Data concerning the evaluation of the subjective 
parameter of hydration indicate that, at the application 
site of the formulation with microparticles, (F1) there was 
an improvement in the sensation of hydration reported 
by 37.1% of the participants on the second day and in all 
participants in the last day. In the left forearm, formulation 
without microparticles (F2), there was an improvement in 
the sensation of hydration in 48.6% on the second day 
and in all participants on the last day. The control was 
evaluated with better hydration by 2.9% of the participants 
on the second day and by 96.7% on the last day.
Discussion
As to age, the participants in this study had 
an average of 26.3 years (Standard deviation 7.80; 
minimum 19; maximum 59). The variability in the 
age of study participants may predict the action of the 
product in different stages of skin aging. This variation 
in the participants’ age has been observed in other 
studies that evaluated the safety and efficacy of new 
formulations(36-38).
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Concerning sex, 30 (85.7%) of the participants 
were female (Table 1). Skin characteristics such as 
erythema, melanin, elasticity, thickness, transepidermal 
water loss and pH vary in the different anatomical sites 
between men and women and also in the different 
age groups(39-42). Authors point out the importance of 
considering variations in the biophysical properties of the 
skin at different ages, genders and anatomical locations 
because these differences are related to individual 
susceptibility to skin diseases; they should be considered 
in studies and in the production of skin products(41).
The same occurs with BMI. This variable influences 
skin quality and, therefore, selecting a sample with a 
wide variation of BMI is important to understand the 
action of the product in a broader way. In this study, BMI 
also varied considerably, with a mean of 23.2 (Standard 
deviation 4.42; minimum 16.1; maximum 32.1).
The quantification of erythema showed that the 
tested formulation did not produce a local inflammatory 
response, since there was no difference between 
average erythema in D0 and D28 (p = 0.8650). The 
first event after the onset of the inflammatory response 
is vasodilation with increased local blood flow, followed 
by increased vascular permeability. These phenomena 
are promoted by chemical mediators and are clinically 
translated into the onset of erythema(43).
The evaluation of melanin showed a difference 
between the averages of the evaluated sites in both 
D0 (p = 0.0037) and D28 (p = 0.0053). These findings 
demonstrate that the amount of melanin was not 
homogeneous at the four sites evaluated at D0 and 
D28. Melanin levels may vary in the different parts of 
the body(41). Besides anatomical issues, this fact can be 
explained by difference in sun exposure(41), corroborating 
with the findings of this study. Personal factors such 
as age, sex, race, anatomical site and skin surface 
properties, as well as environmental factors such as light 
conditions, temperature, humidity and climatic variations 
can influence the color of the skin(41,44).
The function of melanin is the protection of the 
DNA of the keratinocytes against radiation(45); it is 
known that its concentration, its type and its location 
represent important factors in the evaluation of 
skin color, as well as in the evaluation of blood flow, 
thickness, softness and degradation of skin proteins(46). 
This fact represents an important measure in the 
evaluation of possible skin changes.
The evaluation of the amount of melanin showed a 
decrease in the average values only at the application 
site of the formulation with microparticles (Figure 3), 
although the analysis did not indicate a statistically 
significant difference (p = 0.8592). This fact may indicate 
a possible photoprotective effect of the formulation with 
microparticles, since this reduction was observed only at 
the application site of this formulation (F1).
A study that evaluated the effects of a tamarind-
containing emulsion on melanin identified a reduction 
in the amount of melanin at the application sites 
and attributed this result to the presence of phenolic 
compounds present in the extract(47). It is known that 
chamomile contains several phenolic compounds in its 
composition, a fact that suggests the need for future 
studies to better investigate this property.
In the pH evaluation, there was no difference 
between the sites in D0 (p = 0.0819), but there was a 
significant difference in D28 (p = 0.0019). Furthermore, 
the mean pH of the skin was similar in the four sites 
evaluated at D0, but there was a change between values 
in D28, without, however, changing the physiological 
values. As this change was also verified in the control of 
the same arm, it can be inferred that this increase is not 
related to the use of the formulation. Furthermore, this 
alteration did not interfere in the values of pH normality 
in the skin.
pH is also a variable that varies in the different body 
regions(42). In this study, it is believed that the difference 
is the result of the application of the formulation with 
chamomile, which caused an increase in its mean value, 
despite remaining within the physiological limits.
No significant alterations were found in the subjective 
evaluations of burning, pruritus and heat, or in the clinical 
evaluation of desquamation. It is known that the three 
components used are released by regulatory agencies, 
studied in different types of research and used for various 
purposes, among them skin treatments and care.
Chamomile extract was evaluated for toxicity, 
presenting safety at the dosages recommended for 
humans, without cytotoxic, genotoxic or mutagenic 
effects(48). The use of chitosan in nanocapsules with 
alginate, for the treatment of infectious or inflammatory 
conditions of the skin showed antibacterial, anti-
inflammatory and controlled release activity, without 
causing skin irritation(49). A study on the toxicity of 
lanolin and its effect on animal cicatrization concluded 
that it has no toxic effect on monocytes, important cells 
of the cicatrization process(50).
As for the participant who was removed from the 
study in D1 due to a report of local reaction, the event 
is attributed to a possible unknown personal sensitivity 
to the components of the formulation, since this was an 
isolated case with spontaneous regression of signs. The 
participant who reported a sensation of pain indicated 
that the pain had a mild degree, with short duration, and 
it was spontaneously relieved.
The evaluation of the skin barrier function showed 
a significant increase in the average of transepidermal 
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water loss at the four evaluated sites (pF1 = 0.0003, pC1 
< 0.0001, pF2 = 0.0004 and pC2 < 0.0001), indicating 
a decrease of the function (Figure 3). Variations in 
transepidermal water loss can be attributed to blood flow, 
skin temperature, lipid content of the stratum corneum 
and degree of corneocyte formation(41-42). The increase in 
transepidermal water loss through the stratum corneum 
in the present study can be attributed to the period of the 
year and to the dry climate of the city in which the study 
was conducted. Studies maintaining a longer evaluation 
time may elucidate the possible influence of these aspects.
The comparison of the results of the four sites 
evaluated (Table 3) showed that there was no difference 
in the average hydration values at D0 (p = 0.4837) 
and D28 (p = 0.1348). As for the average values of 
transepidermal water loss, a difference was observed 
between the groups at D0 (p = 0.0006) and D28 (p 
= 0.0029). This data demonstrates non-homogeneity in 
the amount of transepidermal water loss between sites 
assessed at the beginning and at the end of the study.
The hydration analysis at the end of the study 
evidenced an increase in the average of this coefficient 
in all the evaluated sites; only the site where the 
formulation with microparticles was applied (F1) (p 
= 0.0483) and the right control (C1) ( p = 0.0413) 
presented a significant difference (Figure 3).
Currently, the prevention of skin lesions is performed 
according to the type of injury. Products of various brands 
are available for application to the whole skin aiming at 
the formation of a protective film and, thus, promoting 
protection against physical or chemical aggressors. 
However, these products do not present chitosan 
microparticles with chamomile; microparticles that 
promote an increase in the stability of the encapsulated 
botanical extract and also the slow and controlled release 
of their actives that can be a differential.
The study had as possible limitations the non-
randomization of the application sites and the non-
measurement of the exact amount of the product to 
be applied.
It is, therefore, a technological product that uses 
in its composition an active principle with proven 
biological activities with the advantage of presenting a 
controlled release, added in a base of known use and 
easy incorporation. Furthermore, these results stimulate 
the continuity of the use of this formulation in animal 
tests for the evaluation of its action in the cicatrization of 
lesions and future clinical studies to evaluate its effect in 
the prevention and also in the treatment of skin lesions 
such as radiodermatitis, peristomal lesions and pressure 
lesions, which are areas of interest for nursing.
Conclusion
The hypothesis that the lanolin formulation, 
containing Chamomilla recutita (L.) rauschert 
microparticles coated with chitosan would be safe for 
application to the intact skin of healthy volunteers was 
confirmed. Despite an isolated case of erythema, this 
event was not observed in other participants. There 
was alteration in melanin, attributed as protective effect 
of the formulation. There was no desquamation; one 
participant reported pain, with spontaneous and brief 
regression. The formulation did not cause pruritus or 
burning in the analyzed period.
The results showed an improvement in skin 
hydration at the application site of the formulation with 
chamomile; the subjective evaluation of the sensation of 
hydration by the volunteers at the end of the period was 
positive in all evaluated sites.
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